Asthma 2014: from monoclonals to the microbiome

Title: Asthma 2014: from monoclonals to the microbiome
Creator: Gibson, Peter G.; Foster, Paul S.
Relation: Lancet Respiratory Medicine Vol. 2, Issue 12, p. 956-958
Publisher Link: http://dx.doi.org/10.1016/S2213-2600(14)70275-9
Publisher: Lancet
Resource Type: journal article
Date: 2014
Description: Asthma is a common disease that continues to plague us. Despite the peaks and troughs in mortality—we are currently in the nadir of a trough—the burden of this illness remains high. Ongoing challenges are prevention, better treatment, and cure. Present treatment for asthma relies on the same drug classes that have been used for decades,namely β agonists and corticosteroids. Targeted therapy for asthma is a new paradigm that holds the promise of improved outcomes through delivery of the right drug to the right person at the right time. However, the feasibility of targeted therapy for asthma and whether it could move beyond refractory disease has been questioned.
Subject: asthma; β agonists; corticosteroids; targeted therapy
Identifier: http://hdl.handle.net/1959.13/1311799
Identifier: uon:22281
Identifier: ISSN:2213-2619
Language: eng

		Thumbnail	File	Description	Size	Format